HUTCHMED (China) Limited (HKEX:13) announced that, as of November 28, 2025, its issued share capital consisted of 872,169,670 ordinary shares of US$0.10 each, with each share carrying one voting right. No shares were held in treasury.

Shareholders may use the figure of 872,169,670 shares as the denominator for calculations under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. For reference, the entire amount of issued ordinary shares is equivalent to the same number of depositary interests on AIM or, if fully converted, 174,433,934 American depositary shares on Nasdaq, with each American depositary share representing five ordinary shares.

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Its portfolio includes three marketed medicines in China, with the earliest of these also approved in major global markets. Further details are available at www.hutch-med.com.